In last trading session, Compass Therapeutics Inc (NASDAQ:CMPX) saw 1.31 million shares changing hands with its beta currently measuring 1.19. Company’s recent per share price level of $2.00 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $276.57M. That closing price of CMPX’s stock is at a discount of -104.0% from its 52-week high price of $4.08 and is indicating a premium of 62.0% from its 52-week low price of $0.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.04 million shares which gives us an average trading volume of 1.48 million if we extend that period to 3-months.
For Compass Therapeutics Inc (CMPX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Compass Therapeutics Inc’s shares saw a change of 37.93% in year-to-date performance and have moved 13.64% in past 5-day. Compass Therapeutics Inc (NASDAQ:CMPX) showed a performance of 16.28% in past 30-days. Number of shares sold short was 7.63 million shares which calculate 3.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 66.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -200.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -200.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -104.70% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -38.89% while estimates for its earnings growth in next 5 years are of 9.27%.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Insiders are in possession of 19.79% of company’s total shares while institution are holding 68.35 percent of that, with stock having share float percentage of 85.21%. Investors also watch the number of corporate investors in a company very closely, which is 68.35% institutions for Compass Therapeutics Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at CMPX for having 22.36 million shares of worth $22.36 million. And as of 2024-06-30, it was holding 16.2534 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0893 of outstanding shares, having a total worth of $11.13 million.
On the other hand, iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.76 shares of worth $5.52 million or 5.29% of the total outstanding shares. The later fund manager was in possession of 2.61 shares on Dec 31, 2024 , making its stake of worth around $5.22 million in the company or a holder of 5.01% of company’s stock.
